Status:
COMPLETED
Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis
Lead Sponsor:
Mayo Clinic
Conditions:
Eosinophilic Esophagitis
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
This study is being done to see if allergy patch testing (APT) can help predict effective dietary therapy in patients with eosinophilic esophagitis.
Detailed Description
Patients are referred to Mayo Clinic Rochester with an establish diagnosis of EoE and are nonresponsive to proton pump inhibitor (PPI) medical therapy. Eligible patients will then meet with one of thr...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Adults ages 18-90
- Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field (eos per HPF) on index esophageal biopsy
- Persistent symptoms and/or greater than or equal to 10 eos per HPF on esophageal biopsy after at least 8 weeks of twice daily PPI therapy
- Exclusion criteria:
- Patients with conditions known to be associated with esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome
- Topical swallowed steroids within 8 weeks of study enrollment
- Dermatologic conditions precluding application of Finn chambers to the skin for APT
- Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy
Exclusion
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2017
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT02227836
Start Date
August 1 2014
End Date
September 1 2017
Last Update
April 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905